20 PARK PLAZA, BOSTON, MA
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
To Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
News
CervoMed Reinforces Neflamapimod's Benefits for DLB at AD/PD™ 2026
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Neflamapimod Elected for Inclusion in UK EXPERTS-ALS Platform Designed to Prioritize Promising Treatments for Amyotrophic Lateral Sclerosis
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRRN14A
Contested Proxy Solicitation Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence